patient suddenly developed hypoglycemia (plasma glucose 36 mg/dl) shortly after breakfast with the injection of 20 units of insulin. Alacepril was switched to temocapril (4 mg/day), another angiotensin-converting enzyme inhibitor on that day, which was stopped on October 4, considering the possibility of hypoglycemia induced by both angiotensin-converting enzyme inhibitors. Since then she has never developed any episode ofhypoglycemia with injection of 10 units of insulin (intermediate-acting insulin; Pen fill N), and gradually her blood glucose levels became higher again (postprandial glucose level: -250 mg/dl), requiring an increase in insulin dose (22 units/day: Pen fill 30R) 5 days after the cessation of the angiotensin-converting enzymeinhibitors. In 1 985, Ferriere et al first reported a case ofhypoglycemia associated with the administration of an angiotensin-converting enzymeinhibitor, captopril (2) . Thereafter there have been several reports ofhypoglycemia associated with the use of angiotensin-converting enzyme inhibitors (3), and hypoglycemia has been recognized as a side effect of angiotensin-converting enzymeinhibitors in Western countries (4) . In contrast, in Japan there have been few reported cases of hypoglycemiawith the administration of angiotensin-converting enzyme inhibitors, except for two cases with enalarpril (5, 6). Here wedescribe a Japanese case ofhypoglycemia associated with the use of alacepril, with which there has been no reports of hypoglycemia. A very recent report from the Netherlands (4) indicated that as many as 1 3.8% of all hospital admissions for hypoglycemia was attributable to use of angiotensin-converting enzymeinhibitors. A euglycemic clamp study was not performed in the present case, but the reduction of required dose of insulin during the use of alacepril and its increase after the cessation of alacepril suggests that the increased insulin sensitivity induced by alacepril might contribute to hypoglycemia. It has recently been suggested that the increased local bradykinin level in muscle is involved in the improvement of insulin sensitivity induced by angiotensin-converting enzyme inhibitors (7) . In the present case, it is possible that impaired renal function exaggerated hypoglycemic action of the angiotensin-converting enzymeinhibitor. Whatever the mechanisms, we should be aware of the possibility of hypoglycemia with angiotensin-converting enzymeinhibitors in Japanese patients as well as Caucasian patients, especially in those associated with diabetic nephropathy (8) .
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